Novo Nordisk A/S (NYSE:NVO) Rating Lowered to “Buy” at StockNews.com

StockNews.com downgraded shares of Novo Nordisk A/S (NYSE:NVO) from a strong-buy rating to a buy rating in a report issued on Sunday morning.

Several other equities analysts have also weighed in on the stock. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $86.02 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $81.50 and a twelve month high of $148.15. The company has a fifty day moving average of $104.70 and a 200-day moving average of $122.21. The firm has a market capitalization of $386.02 billion, a P/E ratio of 27.84, a P/E/G ratio of 1.37 and a beta of 0.40.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NVO. Natixis Advisors LLC raised its position in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares during the last quarter. Zions Bancorporation N.A. raised its holdings in shares of Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Novo Nordisk A/S by 14.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after purchasing an additional 37,346 shares in the last quarter. LRI Investments LLC boosted its holdings in Novo Nordisk A/S by 103.4% during the third quarter. LRI Investments LLC now owns 12,884 shares of the company’s stock worth $1,534,000 after purchasing an additional 6,550 shares during the last quarter. Finally, Destination Wealth Management grew its position in Novo Nordisk A/S by 5.8% in the 3rd quarter. Destination Wealth Management now owns 158,898 shares of the company’s stock worth $18,920,000 after purchasing an additional 8,780 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.